1 |
Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology [J]. Thyroid, 2017, 27(11): 1341-1346.
|
2 |
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J]. Thyroid, 2016, 26(1): 1-133.
|
3 |
Bayona A, Benavent P, Muriel A, et al. Outcomes of repeat fineneedle aspiration biopsy for AUS/FLUS thyroid nodules [J]. Eur J Endocrinol, 2021, 185(4): 497-506.
|
4 |
Goh X, Ting Y, Nga ME, et al. Diagnostic thyroid lobectomy versus active surveillance in the management of Bethesda class Ⅲ thyroid nodules [J]. Asian J Surg, 2020, 43(11): 1108-1109.
|
5 |
Zhao CK, Zheng JY, Sun LP, et al. BRAF V600E mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false-positive and false-negative results [J]. Cancer Med, 2019, 8(12): 5577-5589.
|
6 |
Jinih M, Foley N, Osho O, et al. BRAFV600E mutation as a predictor of thyroid malignancy in indeterminate nodules: a systematic review and meta-analysis [J]. Eur J Surg Oncol, 2017, 43(7): 1219-1227.
|
7 |
Magri F, Chytiris S, Croce L, et al. Performance of the ACR TI-RADS and EU TI-RADS scoring systems in the diagnostic work-up of thyroid nodules in a real-life series using histology as reference standard [J]. Eur J Endocrinol, 2020, 183(5): 521-528.
|
8 |
曹建辉, 黄伟伟, 潘敏强, 等. ACR TI-RADS与Kwak TI-RADS对甲状腺峡部结节的诊断价值 [J/OL]. 中华医学超声杂志(电子版), 2021, 18(2): 164-170.
|
9 |
Ahmadi S, Herbst R, Oyekunle T, et al. Using the ATA and ACR TI-RADS sonographic classifications as adjunctive predictors of malignancy for indeterminate thyroid nodules [J]. Endocr Pract, 2019, 25(9): 908-917.
|
10 |
王剑翔, 俞飞虹, 叶新华, 等. 超声联合BRAF V600E检测对BSRTC Ⅲ类甲状腺结节的诊断价值 [J/OL]. 中华医学超声杂志(电子版), 2020, 17(12): 1178-1182.
|
11 |
王也, 姜睿盈, 底锦熙, 等. RAS、BRAF、TERT基因在甲状腺细针穿刺样本中的表达特点 [J]. 诊断病理学杂志, 2020, 27(11): 769-774.
|
12 |
Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee [J]. J Am Coll Radiol, 2017, 14(5): 587-595.
|
13 |
Li X, Kwon H. The impact of BRAF mutation on the recurrence of papillary thyroid carcinoma: a meta-analysis [J]. Cancers (Basel), 2020, 12(8): 2056.
|
14 |
Trimboli P, Treglia G, Condorelli E, et al. BRAF-mutated carcinomas among thyroid nodules with prior indeterminate FNA report: a systematic review and meta-analysis [J]. Clin Endocrinol (Oxf), 2016, 84(3): 315-320.
|
15 |
Pongsapich W, Chongkolwatana C, Poungvarin N, et al. BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma [J]. Onco Targets Ther, 2019, 12: 1465-1473.
|
16 |
Jinih M, Foley N, Osho O, et al. BRAF V600E mutation as a predictor of thyroid malignancy in indeterminate nodules: A systematic review and meta-analysis [J]. Eur J Surg Oncol, 2017, 43(7): 1219-1227.
|
17 |
Zhang WB, Li JJ, Chen XY, et al. SWE combined with ACR TI-RADS categories for malignancy risk stratification of thyroid nodules with indeterminate FNA cytology [J]. Clin Hemorheol Microcirc, 2020, 76(3): 381-390.
|
18 |
Agretti P, Niccolai F, Rago T, et al. BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency [J]. J Endocrinol Invest, 2014, 37(10): 1009-1014.
|